ABSTRACT
Background Without aggressive treatment, pulmonary arterial hypertension (PAH) has a 5-year mortality of approximately 40%. A patient’s response to vasodilators at diagnosis impacts the therapeutic options and prognosis. We hypothesized that analyzing perfusion images acquired before and during vasodilation could identify characteristic differences between PAH and control subjects.
Methods We studied 5 controls and 4 subjects with PAH using HRCT and 13NN PET imaging of pulmonary perfusion and ventilation. The total spatial heterogeneity of perfusion (CV2Qtotal) and its components in the vertical (CV2Qvgrad) and cranio-caudal (CV2Qzgrad) directions, and the residual heterogeneity (CV2Qr), were assessed at baseline and while breathing oxygen and nitric oxide (O2+iNO). The length scale spectrum of CV2Qr was determined from 10 to 110 mm, and the response of regional perfusion to O2+iNO was calculated as the mean of absolute differences. Vertical gradients in perfusion (Qvgrad) were derived from perfusion images, and ventilation-perfusion distributions from images of 13NN washout kinetics.
Results O2+iNO significantly enhanced perfusion distribution differences between PAH and controls, allowing differentiation between PAH subjects from controls. During O2+iNO, CV2Qvgrad was significantly higher in controls than in PAH (0.08 (0.055-0.10) vs. 6.7 × 10−3 (2×10−4-0.02), p<0.001) with a considerable gap between groups. Qvgrad and CV2Qtotal showed smaller differences: –7.3 vs. -2.5, p = 0.002, and 0.12 vs. 0.06, p = 0.01. CV2Qvgrad had the largest effect size among the primary parameters during O2+iNO. CV2Qr, and its length scale spectrum were similar in PAH and controls. Ventilation-perfusion distributions showed a trend towards a difference between PAH and controls at baseline, but it was not statistically significant.
Conclusions Perfusion imaging during O2+iNO showed a significant difference in the heterogeneity associated with the vertical gradient in perfusion, distinguishing in this small cohort study PAH subjects from controls.
Trial registration Not applicable
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Support for this research was provided by an unrestricted grant from United Therapeutics. The sponsor was not involved in the study design, analysis, or reporting of study findings.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board of the Massachusetts General Hospital. Informed consent was obtained from each subject before the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We edited the abstract and the study's limitations to improve transparency and clarity. Additionally, we revised the language of the introduction.
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
ABBREVIATIONS
- 13NN
- Isotope nitrogen-13 in a molecule bound to a stable nitrogen atom
- 2D
- two-dimensional
- 3D
- three-dimensional
- 6MWD
- six-minute walk distance
- AIC
- Akaike Information Criterion
- CV2
- squared coefficient of variation quantifying heterogeneity
- CV2Q10-30
- heterogeneity of perfusion at the length scale of 10 to 30 millimeter
- CV2Qr
- residual heterogeneity of perfusion
- CV2Qtotal
- total spatial heterogeneity of perfusion
- CV2Qvgrad
- heterogeneity of perfusion associated with the vertical (dorso-ventral) gradient in perfusion
- CV2Qzgrad
- heterogeneity of perfusion associated with the z-axail (cranio-caudal) gradient in perfusion
- FEV1
- forced expiratory volume in first second
- Fgas
- gas fraction images using
- Ftis
- tissue fraction
- FWHM
- full-width at half maximum
- FVC
- forced vital capacity
- HRCT
- high resolution computed tomography
- HU
- Hounsfield units
- MLV
- mean lung volume
- mPAP
- mean pulmonary arterial pressure
- MRI
- magnetic resonance imaging
- O2+iNO
- inhalation of nitric oxide (iNO) with balance gas oxygen (O2)
- PAH
- pulmonary arterial hypertension
- PCWP
- pulmonary capillary wedge pressure
- PET-CT
- positron-emission tomography and high-resolution computer tomography
- PVR
- pulmonary vascular resistance
- Qvgrad
- vertical (dorso-ventral) gradient in perfusion
- Qvoxel
- perfusion of a voxel
- RHC
- right heart catheterization
- ROI
- region of interest
- SD Q
- dispersions of perfusion
- SD V
- dispersions of ventilation
- SPECT
- single-photon emission computed tomography
- specific ventilation
- TLC
- total lung capacity
- ventilation/perfusion
- alveolar ventilation